Sung Won Song
Director/Board Member at JW (CAYMAN) THERAPEUTICS CO. LTD
Sung Won Song active positions
| Companies | Position | Start | End |
|---|---|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Director/Board Member | 28/08/2023 | - |
EpimAb Biotherapeutics, Inc.
 EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Director/Board Member | - | - |
Career history of Sung Won Song
Training of Sung Won Song
| Korea University | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| The Ohio State University | Doctorate Degree |
Statistics
International
| China | 3 |
| United States | 3 |
| South Korea | 2 |
Operational
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| JW (CAYMAN) THERAPEUTICS CO. LTD | Health Technology |
| Private companies | 1 |
|---|---|
EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology EpimAb Biotherapeutics, Inc. is a Chinese clinical stage biopharmaceutical company that specializes in developing multispecific antibodies. The company is based in Shanghai, China. The company utilizes its in-house research and technology capabilities, including the proprietary fit-ig® and mat-fab bispecific platforms, to generate and advance a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. The company was founded in 2016 by Chen Bing Wu, who has been the CEO since 2016. | Health Technology |
- Stock Market
- Insiders
- Sung Won Song
- Experience
